Sign in
Active, not recruitingNo phase

Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases

Key facts

Who runs it
University Hospital Heidelberg
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
90 people, planned
Started
1 Feb 2024
Expected to end
1 May 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Preoperative Radiotherapy
  • Intraoperative Radiation
  • Postoperative Radiotherapy
Record updated
27 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Histologically confirmed solid malignancy; Metastatic brain disease (1-10 brain metastases), with at least one brain metastasis in a non-eloquent location (i.e. motor or speech) planned for resection; Maximum size of the brain metastasis <5cm; Eligibility of patients for both stereotactic radiotherapy and resection; Time interval from resection to adjuvant stereotactic radiosurgery of 2-6 weeks; Time interval from neoadjuvant stereotactic radiosurgery to resection of 1-7 days; Possibility to postpone resection for neoadjuvant stereotactic radiosurgery, if applicable; Karnofsky performance scores >= 70 or Eastern Cooperative Oncology Group (ECOG) >= 2 at enrollment; Age ≥ 18 years of age; For women with childbearing potential, (and men) adequate contraception; Ability of subject to understand character and individual consequences of the clinical trial; Written informed consent (must be available before enrolment in the trial)

Who cannot take part

  • Necessity of immediate surgical resection due to life threatening symptoms
  • Previous radiotherapy of the brain
  • Small-cell lung cancer (SCLC) or hematologic malignancy as primary malignant illness
  • Leptomeningeal disease suspected RadCav Trial Protocol Version 1.1, 01.07.2022 18
  • brain metastasis directly located (≤10mm) next to the optic system or brain stem
  • Refusal of the patients to take part in the study
  • Contraindication for contrast-enhanced MRI
  • Pregnant or lactating women
  • Participation in another competing clinical study or observation period of competing trials, respectively

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients suffering from malignancies in advanced stages often develop brain metastases, which limit both the life span and the quality of life.

Read full original descriptionShow less

Combining surgery and radiotherapy for resectable brain metastases is standard of care but there is a lot of controversy on which kind of radiotherapy is best suitable. Recently, first volumetric in-silico analyses point to theoretical advantages of neoadjuvant stereotactic radiotherapy of brain metastases. Special about this trial is the direct comparison between the three currently discussed radiotherapy options for resectable brain metastases: Neoadjuvant stereotactic radiotherapy, intraoperative radiotherapy and adjuvant stereotactic radiotherapy.

The 3 groups in the trial

  • Experimental Arm A (Preoperativ SRS)Treatment being tested

    Preoperative stereotatic radiosurgery following resection of brain metastases after 1-7 days

    Treatment: Preoperative Radiotherapy

  • Experimental Arm B (Intraoperativ SRS)Treatment being tested

    Intraoperative stereotactic radiotherapy after resection of brain metastases

    Treatment: Intraoperative Radiation

  • Standard Treatment Arm C (Posoperativ SRS)Existing treatment, for comparison

    Resection of brain metastases following stereotactic radiotherapy after 2-6 weeks

    Treatment: Postoperative Radiotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases - A Prospective Randomized Explorative Phase II Trial
Record updated
27 May 2026